Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2014

01-04-2014 | Original Article

Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints

Authors: Agnese Picco, M. Cristina Polidori, Michela Ferrara, Roberta Cecchetti, Dario Arnaldi, Mauro Baglioni, Silvia Morbelli, Patrizia Bastiani, Irene Bossert, Giuliana Fiorucci, Andrea Brugnolo, Massimo Eugenio Dottorini, Flavio Nobili, Patrizia Mecocci

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2014

Login to get access

Abstract

Purpose

The role of oxidative stress is increasingly recognized in cognitive disorders of the elderly, notably Alzheimer’s disease (AD). In these subjects brain18F-FDG PET is regarded as a reliable biomarker of neurodegeneration. We hypothesized that oxidative stress could play a role in impairing brain glucose utilization in elderly subjects with increasing severity of cognitive disturbance.

Methods

The study group comprised 85 subjects with cognitive disturbance of increasing degrees of severity including 23 subjects with subjective cognitive impairment (SCI), 28 patients with mild cognitive impairment and 34 patients with mild AD. In all subjects brain FDG PET was performed and plasma activities of extracellular superoxide dismutase (eSOD), catalase and glutathione peroxidase were measured. Voxel-based analysis (SPM8) was used to compare FDG PET between groups and to evaluate correlations between plasma antioxidants and glucose metabolism in the whole group of subjects, correcting for age and Mini-Mental State Examination score.

Results

Brain glucose metabolism progressively decreased in the bilateral posterior temporoparietal and cingulate cortices across the three groups, from SCI to mild AD. eSOD activity was positively correlated with glucose metabolism in a large area of the left temporal lobe including the superior, middle and inferior temporal gyri and the fusiform gyrus.

Conclusion

These results suggest a role of oxidative stress in the impairment of glucose utilization in the left temporal lobe structures in elderly patients with cognitive abnormalities, including AD and conditions predisposing to AD. Further studies exploring the oxidative stress–energy metabolism axis are considered worthwhile in larger groups of these patients in order to identify pivotal pathophysiological mechanisms and innovative therapeutic opportunities.
Literature
1.
Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19:823–35.PubMedCrossRef
2.
Smith MA, Nunomura A, Lee HG, Zhu X, Moreira PI, Avila J, et al. Chronological primacy of oxidative stress in Alzheimer’s disease. Neurobiol Aging. 2005;26:579–80.PubMedCrossRef
3.
Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med. 2004;25:17–26.PubMedCrossRef
4.
5.
Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2010;469:6–10.PubMedCrossRef
6.
Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985;311:617–31.PubMedCrossRef
7.
Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005;92:628–36.PubMedCrossRef
8.
Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem. 2008;104:683–95.PubMedCentralPubMed
9.
Butterfield DA, Griffin S, Munch G, Pasinetti G. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer’s disease brain exists. J Alzheimers Dis. 2002;4:193–201.PubMed
10.
Behl C. Oxidative stress in Alzheimer’s disease: implications for prevention and therapy. Subcell Biochem. 2005;38:65–78.PubMedCrossRef
11.
Gòmez-Ramos A, Dìaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res. 2003;71:863–70.PubMedCrossRef
12.
Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880–8.PubMed
13.
14.
Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:65–75.PubMedCrossRef
15.
Allaman I, Bélanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011;34:76–87.PubMedCrossRef
16.
Massaad CA, Pautler RG, Klann E. Mitochondrial superoxide: a key player in Alzheimer’s disease. Aging (Albany NY). 2005;1:758–61.
17.
18.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. European task force on age-related white matter changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMedCrossRef
19.
Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.PubMedCrossRef
20.
Lawton MP, Brody EM. Assessment of older people; self maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedCrossRef
21.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRef
22.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedCentralPubMedCrossRef
23.
Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399–401.PubMedCrossRef
24.
Rey A. L’examenclinique en psychologie. Paris: Presses Universitaires de France; 1958.
25.
Novelli G, Papagno C, Capitani E, Laiacona M, Cappa SF. Tre test clinici di memoria verbale a lungo termine: taratura su soggetti normali. Arch Psicol Neurol Psichiatria. 2013;47:278–96.
26.
Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analysis of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur Neurol. 1996;36:378–84.PubMedCrossRef
27.
28.
L’Abbé MR, Fisher PWF. Automated assay of superoxide dismutase in blood. Methods Enzymol. 1990;186:232–7.PubMedCrossRef
29.
Sandström J, Nilsson P, Karlsson K, Marklund SL. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem. 1994;269:19163–6.PubMed
30.
Zhou LC, Xiang W, Potts J, Floyd M, Sharan C, Yang H, et al. Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med. 2006;41:1384–91.PubMedCrossRef
31.
32.
Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952;195:133–40.PubMed
33.
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.PubMedCrossRef
34.
Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, Van Berckel BN, et al. Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33:2533–50.PubMedCrossRef
35.
Gispert JD, Pascau J, Reig S, Martínez-Lázaro R, Molina V, García-Barreno P, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19:601–12.PubMedCrossRef
36.
Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708–15.PubMedCrossRef
37.
Rodriguez G, Morbelli S, Brugnolo A, Calvini P, Girtler N, Piccardo A, et al. Global cognitive impairment should be taken into account in SPECT-neuropsychology correlations: the example of verbal memory in very mild Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1186–92.PubMedCrossRef
38.
Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337–49.PubMedCrossRef
39.
Tasaki H, Yamashita K, Tsutsui M, Kamezaki F, Kubara T, Tanaka S, et al. Heparin-released extracellular superoxide dismutase is reduced in patients with coronary artery atherosclerosis. Atherosclerosis. 2006;187:131–8.PubMedCrossRef
40.
De la Torre JC. Alzheimer’s disease: how does it start? J Alzheimers Dis. 2002;4:497–512.PubMed
41.
Polidori MC, Pientka L. Bridging the pathophysiology of Alzheimer’s disease with vascular pathology: the feed-back, the feed-forward, and oxidative stress. J Alzheimers Dis. 2012;28:1–9.PubMed
42.
Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging. 2003;24:915–9.PubMedCrossRef
43.
Baumbach GL, Didion SP, Faraci FM. Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase. Stroke. 2006;37:1850–5.PubMedCrossRef
44.
Didion SP, Hathaway CA, Faraci FM. Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD. Am J Physiol Heart Circ Physiol. 2001;281:H1697–703.PubMed
45.
Yada T, Shimokawa H, Morikawa K, Takaki A, Shinozaki Y, Mori H, et al. Role of Cu, Zn-SOD in the synthesis of endogenous vasodilator hydrogen peroxide during reactive hyperemia in mouse mesenteric microcirculation in vivo. Am J Physiol Heart Circ Physiol. 2008;294:H441–8.PubMedCrossRef
46.
Demchenko IT, Gutsaeva DR, Moskvin AN, Zhilyaev SY. Involvement of extracellular superoxide dismutase in regulating brain blood flow. Neurosci Behav Physiol. 2010;40:173–8.PubMedCrossRef
47.
Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322:254–62.PubMedCrossRef
48.
Rajagopalan P, Toga AW, Jack CR, Weiner MW, Thompson PM. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport. 2013;24:58–62.PubMedCentralPubMedCrossRef
49.
Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One. 2013;8:e55531.PubMedCentralPubMedCrossRef
50.
den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126:170–5.CrossRef
51.
Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology. Brain Pathol. 2010;20:222–33.PubMedCrossRef
52.
Limón ID, Díaz A, Mendieta L, Chamorro G, Espinosa B, Zenteno E, et al. Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats. Neurosci Res. 2009;63:129–37.PubMedCrossRef
53.
Wang J, Xiong S, Xie C, Markesbery WR. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem. 2005;93:953–62.PubMedCrossRef
54.
Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr. 2009;41:441–6.PubMedCentralPubMedCrossRef
55.
Hovorkova P, Kristofikova Z, Horinek A, Ripova D, Majer E, Zach P, et al. Lateralization of 17beta-hydroxysteroid dehydrogenase type 10 in hippocampi of demented and psychotic people. Dement Geriatr Cogn Disord. 2008;26:193–8.PubMedCrossRef
56.
57.
Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36–45.PubMedCrossRef
58.
Bozzali M, Padovani A, Caltagirone C, Borroni B. Regional grey matter loss and brain disconnection across Alzheimer disease evolution. Curr Med Chem. 2011;18:2452–8.PubMedCrossRef
59.
Bozoki AC, Korolev IO, Davis NC, Hoisington LA, Berger KL. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer’s disease: a DTI/FDG-PET study. Hum Brain Mapp. 2012;33:1792–802.PubMedCrossRef
60.
Grimmer T, Faust M, Auer F, Alexopoulos P, Förstl H, Henriksen G, et al. White matter hyperintensities predict amyloid increase in Alzheimer’s disease. Neurobiol Aging. 2012;33:2766–73.PubMedCrossRef
61.
Clausen A, Xu X, Bi X, Baudry M. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer’s disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J Alzheimers Dis. 2012;30:183–208.PubMed
Metadata
Title
Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints
Authors
Agnese Picco
M. Cristina Polidori
Michela Ferrara
Roberta Cecchetti
Dario Arnaldi
Mauro Baglioni
Silvia Morbelli
Patrizia Bastiani
Irene Bossert
Giuliana Fiorucci
Andrea Brugnolo
Massimo Eugenio Dottorini
Flavio Nobili
Patrizia Mecocci
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2638-x

Other articles of this Issue 4/2014

European Journal of Nuclear Medicine and Molecular Imaging 4/2014 Go to the issue

Original Article

18F-FDG PET and intravascular ultrasonography (IVUS) images compared with histology of atherosclerotic plaques: 18F-FDG accumulates in foamy macrophages

Original Article

Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study

Editorial Commentary

Amyloid imaging in depression: a predictor of Alzheimer’s disease?

Original Article

Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma

Original Article

FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity

Original Article

Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET